Clinical Trials Arena October 23, 2024
Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.
As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and prevention strategies highlight both progress and the ongoing challenges in the field. Recent findings presented at IDWeek 2024 offered crucial insights into prevention, treatment, and policy for those affected by HIV.
The HIV prevention landscape for cisgender women remains limited despite the availability of options such as emtricitabine/tenofovir disoproxil fumarate, cabotegravir, and the dapivirine ring. While effective, adherence to these methods remains low, and alternatives are needed to fit women’s varied preferences, including solutions for pregnant women. Notably, emtricitabine/tenofovir alafenamide (F/TAF) has yet to receive approval for cisgender...
Today's Sponsors
Today's Sponsor